Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors.

The development of immune checkpoint inhibitors (ICIs) has a tremendous effect on the treatment options for multiple types of cancer. Nonetheless, there is a large interpatient variability in response, survival, and the development of immune-related adverse events (irAEs). Pharmacogenetics is the general term for germline genetic variations, which may cause the observed interindividual differences in response or toxicity to treatment.

When crisis hits: Bike-Sharing platforms amid the Covid-19 pandemic.

In this work, we examine the changes in demand for bike-sharing platforms with the onset of the Covid-19 pandemic. Using the fixed-effects regression formulation of difference-in-differences, we evaluate how the demand for bike-sharing platforms changed after the first cases of Covid were discovered and after the first executive orders were implemented. Accounting for weather conditions, socio-economic characteristics, time trends, and fixed effects across cities, our findings indicate that there is an increase in daily bike-sharing trips by 22% on average after the first Covid-19 case diagnosis, and a decrease of 30% after the first executive order implementation in each municipality, using the data up to August 2020.

The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.

Introduction: Immune checkpoint inhibitor (ICI) associated diabetes is a harmful adverse event (AE) in patients with cancer following anti-programmed (cell) death protein-1 (PD-1) treatment. There are no available biomarkers able to predict this AE. The primary aim of this study was to investigate C-peptide levels as potential predictor for the occurrence of ICI-related diabetes.

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.

Aim: With increasing use of immune checkpoint inhibitors (ICIs) more patients will develop severe and potentially life-threatening immune-related adverse events (irAEs). So far, predictive models for the occurrence of grade ≥3 irAEs are lacking. Therefore, we analysed associations between patient and disease characteristics, and the occurrence of grade ≥3 irAEs.